Across TCGA pan-cancer cohorts, B4GALNT3 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of B4GALNT3’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where B4GALNT3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types B4GALNT3 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.
LSCC are the cancer types where B4GALNT3 tumor–normal differential expression is most reproducible.